Pembrolizumab plus enfortumab vedotin in urothelial cancer-Reference-Cited by-同舟云学术

Pembrolizumab plus enfortumab vedotin in urothelial cancer

Published:2024-01-24 Issue:7 Volume:21 Page:387-388
ISSN:1759-4812
Container-title:Nature Reviews Urology
language:en
Short-container-title:Nat Rev Urol

Author:

Santoni Matteo,Takeshita Hideki^ORCID,Massari Francesco^ORCID,Bamias Aristotelis,Cerbone Linda,Fiala Ondrej,Mollica Veronica,Buti Sebastiano^ORCID,Santoni Angela,Bellmunt Joaquim^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41585-024-00858-y.pdf

Reference10 articles.

1. Powles, T. B. et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann. Oncol. 34 (Suppl. 2), S1340 (2023).

2. Chikuma, S. et al. PD-1-mediated suppression of IL-2 production induces CD8+ T cell energy? in vivo. J. Immunol. 182, 6682–6689 (2009).

3. Milella, M. et al. Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. Br. J. Cancer 79, 770–779 (1999).

4. Sakatani, T. et al. IFN-gamma expression in the tumor microenvironment and CD8-positive tumor-infiltrating lymphocytes as prognostic markers in urothelial cancer patients receiving pembrolizumab. Cancers 14, 263 (2022).

5. Baker, S. C. et al. The urothelial transcriptomic response to interferon gamma: implications for bladder cancer prognosis and immunotherapy. Cancers 14, 5295 (2022).

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer;Cancers;2024-09-04

2. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence;Life Sciences;2024-09